BioMarin Pharmaceuticals BMRN Debt Instrument, Fair Value Disclosure

Debt Instrument, Fair Value Disclosure at other companies

Arch Capital GroupACGL

$566.2M+2.5%

Bank of AmericaBAC

$820B-2.7%

LennarLEN

$4.11B+85.3%

Chicago Atlantic Real Estate FinanceREFI

$29.25M—

EFC

Ellington Financial Inc.EFC

$3.13B+62.2%

NRZ

New Residential Investment Corp.NRZ

——

Other financials

Income statement

See full

Revenue$766.2M+2.8%

Gross profit$571.2M-3.8%

Operating income$129.6M-42.1%

Net income$105.5M-43.2%

EPS (diluted)$0.54-43.2%

Balance sheet

See full

Cash & equivalents$3.1B+193%

Total debt$1.4B+138%

Total equity$6.2B+7.2%

Total assets$8.6B+20.2%

Cash flow

See full

Operating cash flow$220.7M+26.5%

CapEx$20.9M+24.8%

Free cash flow$199.7M+26.7%

Valuation

See full

Market cap$10.57B-19.4%

Enterprise value$8.93B-29.3%

P/E21.1×-22.7×

P/S3.3×-1.2×

Profitability

See full

Gross margin76.5%-2.9pp

Operating margin19.9%+7.2pp

Net margin16.8%+5.1pp

FCF margin23.7%+2.5pp

Returns & leverage

See full

Return on equity9.1%+2.8pp

Debt / equity0.2×+0.1×

Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentFairValue.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's debt instrument, fair value disclosure.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioMarin Pharmaceuticals's debt instrument, fair value disclosure?: BioMarin Pharmaceuticals (BMRN) reported debt instrument, fair value disclosure of $1.42B in Q1 2026.